1. Market Research
  2. > Pathology
About 100 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)

  • $ 900
  • June 2020
  • 82 pages

B-cell lymphomas can be categorized into aggressive NHL, such as diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and burkitt' s lymphoma (BL), and indolent NHL, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma

  • Autoimmune Disease
  • Lymphoma
  • Therapy
  • World
  • AstraZeneca PLC

Vaginal Cancer - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 381 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Lung Cancer
  • Lymphoma
  • Sexually Transmitted Disease
  • United States
  • AstraZeneca PLC

Prostate Cancer: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • August 2019
  • 212 pages

BAY-##, AN ORAL ATR INHIBITOR, IS BEING INVESTIGATED IN A PHASE I STUDY (BAYER, NCT##) IN SOLID TUMORS (INCLUDING PCA) AND LYMPHOMAS.

  • Hospital
  • Lymphoma
  • Prostate Cancer
  • Therapy
  • AstraZeneca PLC

Chronic Lymphocytic Leukemia - Competitive Landscape to 2030

  • $ 3495
  • May 2020
  • 55 pages

Lung Cancer Breast Cancer Leukemia Lymphoma Non-Small Cell Lung...

  • Leukemia
  • Lymphoma
  • AbbVie Inc.
  • AstraZeneca PLC
  • Roche Group

Vaginal Cancer - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 351 pages

It is in Phase I stage of development for diffuse large B cell lymphoma and high-grade B cell lymphoma.

  • Cancer
  • Lung Cancer
  • Lymphoma
  • United States
  • AstraZeneca PLC

Nanopharmaceuticals - Thematic Research

  • $ 1950
  • March 2020
  • 96 pages

RAKUTEN MEDICAL IS HEADQUARTERED IN SAN DIEGO, CALIFORNIA, US. © GlobalData Abbreviations European Medicines Agency distearoylphosphatidylcholine dimethyl hydrazide diabetic macular edema diffuse large B-cell lymphoma cardiovascular Cutaneous T-cell lymphoma Complete Response Letter central

  • Lymphoma
  • Therapy
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Potential Pipeline Disruptors

  • $ 4200
  • May 2017
  • 120 pages

FOLLICULAR LYMPHOMA TENDS TO BE INDOLENT AND DIFFUSE LYMPHOMA TENDS TO BE AGGRESSIVE.

  • Lymphoma
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • AstraZeneca PLC

Global Clinical Trials - Current Trends and Recent Advancement

  • $ 2995
  • January 2019
  • 65 pages

Indication Lung cancer 2013 2014 2015 2016 2017 2018 ## ## ## ## ## ## Breast cancer ## ## ## ## ## ## Lymphoma Leukemia Gynecological cancer CRC Skin cancer Ovarian cancer Prostate cancer Melanoma ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Clinical Trial
  • Drug Development
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.

The Chinese Pharmaceutical Market to 2030

  • $ 3000
  • March 2020
  • 101 pages

-Increase your foothold in the Chinese market TODAY -Establish partnerships to manufacture, distribute or develop Chinese products -Scope out the market prior to entry   This new report covers the ...

  • Pharmaceutical
  • China
  • East Asia
  • AstraZeneca PLC
  • Fosun International Limited

Global Central Nervous System Therapeutic Market - Opportunities and Forecast (2014-2024)

  • $ 2200
  • March 2019
  • 214 pages

There are several types of brain tumor depending upon the kind of cell which is infected such as gilomas, epidermoid, lymphoma, meningioma etc.

  • Health Services
  • Lymphoma
  • Neurology
  • World
  • AstraZeneca PLC

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Saudi Arabia

  • $ 1995
  • August 2019
  • 140 pages

GSK discontinued the global development of GSK-## in Phase I development for relapsed or refractory small-cell lung cancer, and GSK-## in Phase I stage of development for follicular lymphoma, diffuse large B-cell lymphoma, solid tumors, and refractory multiple myeloma.

  • Lymphoma
  • Medical Device
  • Pharmaceutical
  • Saudi Arabia
  • AstraZeneca PLC

Global Gene Therapy Market Report - 2026

  • $ 3849
  • July 2018
  • 105 pages

Lymphoma, B-Cell Lymphoma Cd##+ Diffuse Large B-Cell Lymphoma Undisclosed (Expected Oncology) Prostate Cancer, Lung Cancer Phase ## CTL## CAR-T Phase ##I BiTE platform CAR-T Phase ## LADD iMultiple Myelomauno-oncology platform Up to ## gene therapies including S##A## Phase ##

  • Gene Therapy
  • Lymphoma
  • Therapy
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH

The State of Personalized/ Precision Medicine

  • $ 7995
  • October 2019
  • 119 pages

BeiGene Ovarian cancer Rhythm Pharmaceuticals Pro-opiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity Denovo Biopharma Diffuse large B-cell lymphoma (DLBCL) Genentech/ Roche Solid tumors GenSight Biologics Leber' s hereditary optic neuropathy (LHON)

  • Lymphoma
  • Therapy
  • United States
  • AstraZeneca PLC
  • Merck & Co., Inc.

Immuno-oncology: Focus on Developments and Opportunities in Immune Checkpoint Modulators

  • $ 7995
  • March 2020
  • 141 pages

In the long term, GlobalData anticipates ICIs having more prominence in the treatment of malignancies such as HL, MM, AML, and other types of lymphomas.

  • Lymphoma
  • Therapy
  • China
  • United States
  • AstraZeneca PLC

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease

  • $ 4995
  • December 2017
  • 160 pages

They also have an increased risk of Parkinson' s disease, and cancers such as myeloma, leukemia and lymphoma.

  • Clinical Trial
  • Genetic Disorder
  • Lymphoma
  • Therapy
  • AstraZeneca PLC

Pharmaceutical Drugs Global Market Report 2018

  • $ 8000
  • March 2018
  • 455 pages

Its importance results from the large population of cancer patients suffering from various types of blood cancers such as leukemia, lymphoma, and myeloma.

  • Healthcare
  • Lymphoma
  • Pharmaceutical
  • Market Size
  • AstraZeneca PLC

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece

  • $ 1995
  • November 2017
  • 149 pages

FOR EXAMPLE, IT DISCONTINUED SAR-##, WHICH WAS IN PHASE I TRIALS FOR THE TREATMENT OF ADVANCED SOLID TUMORS OR LYMPHOMAS, METASTATIC BRAF-MUTATED MELANOMA AND PTEN-DEFICIENT TUMORS, IN FEBRUARY 2015.

  • Healthcare
  • Hospital
  • Lymphoma
  • Pharmaceutical
  • AstraZeneca PLC

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

  • $ 4995
  • September 2017
  • 137 pages

Numerous intracellular substrates such as insulin receptor substrate (IRS) proteins, casitas B-lineage lymphoma (CBL), adapter proteins with a pleckstrin homology (PH) and Src Homology ## (SH##) domain and GRB##-associated-binding protein ## (GAB##) are activated upon binding of the insulin rece

  • Clinical Trial
  • Diabetes
  • Insulin
  • Lymphoma
  • AstraZeneca PLC

The World Market for Cancer Therapeutics by Product

  • $ 4200
  • November 2015
  • 320 pages

Follicular lymphoma tends to be indolent and diffuse lymphoma tends to be aggressive.

  • Cancer
  • Lymphoma
  • Targeted Therapy
  • Therapy
  • AstraZeneca PLC

Head and Neck Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Immunotherapies and Increasing Prevalence to Drive the Market

  • $ 4995
  • December 2017
  • 155 pages

Avelumab is being investigated in multiple tumor types, such as breast cancer, ovarian cancer, fallopian tube cancer, melanoma, RCC, HCC, small cell lung cancer, NSCLC, prostate cancer, gastric cancer, CRC, cervical cancer, diffuse large B-cell lymphoma, acute myeloid leukemia, osteosarcoma

  • Cancer
  • Chemotherapy
  • Lymphoma
  • Therapy
  • AstraZeneca PLC
View report >

Vaccine Market in the US - Forecast, Monthly Update

  • June 2020
  • 16 pages

lymphoma Closed $##. ## billion deal of The Medicines Co., with new drug for elevated LDL-C - ## - GLAXOSMITHKLINE PLC (GSK: BUY) Products/ processes fighting COVID-## Earnings Expected to Rise LSD over next two years " Company' s primary aim is to develop multiple adjuvanted COVI

  • Lymphoma
  • Vaccine
  • United States
  • AstraZeneca PLC
  • Bio-Techne Corporation

Cancer Statistics July 2019

Therapy Market in the US November 2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on